

Under-represented Populations Awaiting OHT

Eileen Hsich, MD

Associate Medical Director for the Heart Transplant
Assistant Professor of Medicine



FEBRUARY 25-27, 2016 • PHOENIX, ARIZONA

Disclosures:Supported by NHLBI under Award Number R56HL125420-01A1

Outline: Under-represented Populations

- Overview
 - Under-represented Populations
 - Outcome
- Limitations in this Field
- Goals for the Future

Under-representation



Populations


- Gender
- Race
- Type of Heart Disease

http://www.healthcentral.com/sites/www.healthcentral.com/files/isolated.jpg

Under-represention: Gender

SRTR 1999-2008

Year	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Women	21%	20%	20%	21%	23%	23%	23%	24%	25%	24%
Men	79%	80%	80%	79%	78%	77%	77%	76%	75%	76%



http://www.srtr.org/annual_Reports/archives/2009/2009_Annual_Report/1101a_can-gender_hr.htm





Under-represention: Race

SRTR 1999-2008


Year	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
White	79%	79%	79%	77%	75%	73%	73%	74%	74%	73%
Black	13%	14%	13%	15%	15%	16%	18%	18%	17%	18%
Asian	1%	1%	2%	2%	2%	2%	2%	2%	2%	2%
Hispanic	6%	6%	6%	6%	8%	8%	7%	6%	7%	7%
Other	0%	0%	0%	1%	1%	1%	1%	1%	1%	1%



http://www.srtr.org/annual_Reports/archives/2009/2009_Annual_Report/iHR_Candidates_race.htm?o=5&g=1&c=3



Under-represention: Type of Heart Disease




RCM: idiopathic, amyloid, endocardial fibrosis, sarcoidosis, XRT/chemotherapy, other

Other: 80% OHT, 20% other






Outcomes



Death and Life 1911 by Gustav Klimt

Outcome: Gender Differences Awaiting OHT

SRTR Database



Http://srtr.Transplant.Hrsa.Gov/annual reports/2010/1103 can-gender hr.Htm



Risk of Being Female Awaiting OHT:

Cox Proportional Hazards Analyses

HR (95% CI)	P value						
1.23 (1.10-1.38)	0.0004						
1.17 (1.03-1.34)	0.0185						
1.10 (0.98-1.23)	0.1234						
1.08 (0.95-1.23)	0.2572						
Status 2							
0.73 (0.66-0.81)	<0.0001						
0.70 (0.63-0.79)	<0.0001						
	1.23 (1.10-1.38) 1.17 (1.03-1.34) 1.10 (0.98-1.23) 1.08 (0.95-1.23) 0.73 (0.66-0.81)						


^{*} Adjusted for age, DM, dialysis, BMI, prior OHT, race, CVA, history of tobacco, inotropes, GFR, ventilator, insurance, type of VAD, antiarrhythmic, prior cardiac surgery, HTN, malignancy, PVD, ECMO, IABP, era, cardiac diagnosis, ABO blood type, defibrillator, pulmonary artery mean, total albumin, and cardiac output with dummy variables for missing GFR, pulmonary artery mean pressure, PCWP mean, cardiac output, and albumin

Hsich et al., JACC HF. 2014;4:347-55



Outcome: Racial Differences

7/12/06-9/30/10 OPTN: Mortality on Waiting List for OHT




Hispanic were at higher risk of wait-list mortality (adjusted hazard ratio 1.51, 95% CI 1.23-1.85) in comparison with White, but not Blacks (adjusted hazard ratio 1.13, 95% CI 0.97-1.31)

T. Singh. Circulation. 2012;125:3022-3030



Outcome: Differences by Heart Disease

2004-2014 SRTR: Two Year Survival on OHT Waitlist



E. Hsich, J.Rogers, D. McNamara, D. Taylor, R. Starling, E. Blackstone, J. Schold. 2016, JAAC: HF in press



Risk of Death Compared to DCM

Cox Proportional Hazards Analyses

Model: Death	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
<u>DCM</u>		
RCM	1.50 (1.27-1.77) *	1.70 (1.43-2.02) *
ICM	1.17 (1.10 -1.24) *	1.10 (1.03-1.18) *
нсм	0.99 (0.79-1.24)	1.23 (0.98-1.54)
Valvular	1.33 (1.10-1.60) *	1.30 (1.07-1.57) *
CHD	0.96 (0.83-1.12)	1.37 (1.17-1.61) *
Other	1.78 (1.60-1.98) *	1.51 (1.34-1.69) *

^{*=}P < 0.05


Adjusted for age, sex, era before/after April 1, 2008, DM, dialysis, BMI, race, CVA, tobacco, inotropes, eGFR, mechanical ventilator, insurance, type of VAD, HTN, malignancy, PVD, ECMO, IABP, ABO blood type, defibrillator, pulmonary artery mean, albumin, and cardiac index

E. Hsich, J.Rogers, D. McNamara, D. Taylor, R. Starling, E. Blackstone, J. Schold. 2016 JAAC: HF in press,




Survival for Patients with Light Chain (AL)-Amyloidosis

Survival Awaiting OHT at MGH



Survival After OHT



M. Semigran, et al. JHLT, 2014-02-01, Volume 33, Issue 2, Pages 149-156



Limitations in the Field



Limitations in the Field

- Limited UNOS/OPTN research
- Important risk factors for survival not required upon data entry
- No specific definitions to define each type of cardiomyopathy

Goals for the Future

- Require essential variables to be entered in the OPTN/UNOS database
- Determine for under-represented populations the risk factors for survival and their interactions
- Require verification of the "type of cardiomyopathy" post OHT
- Create a heart transplant allocation score

Conclusions: HF in Women

- Under-represented populations: Women, non-whites, all cardiomyopathies except ICM and NICM
- High Wait-list Mortality
 - F >M initially listed as UNOS Status 1A
 - Hispanic> White
 - RCM > DCM
- HCM has a similar waitlist mortality to DCM

The End

